Christopher Wright, MD, PhD, has been tapped as the first chief medical officer and head of translational research for Ring Therapeutics, a gene therapy company. He will assume his new role Feb. 7.
Dr. Wright joins Ring from AavantiBio, where he served as chief medical officer. He has also served as chief medical officer of Cyclerion Therapeutics and senior vice president and chief development officer of Ironwood Pharmaceuticals, according to a Jan. 30 news release from Ring Therapeutics.
Dr. Wright currently serves as a medical adviser to Cyclerion and on the board of directors for Alkermes.